Interferon beta-1a; Alemtuzumab 12 mg; Alemtuzumab 24 mg
A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00050778/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–50 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 334 чел. во всех странах исследования.
- Центров в реестре: 6 в 2 городах. Список — ниже на странице.
- Плановая дата окончания (01.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 21
Критерии включения
- Signed informed consent form (ICF)
- Male or non-pregnant, non-lactating female participants, 18 to 50 years of age (inclusive) as of signing the ICF
- Diagnosis of MS per McDonald's update of the Poser criteria, including cranial MRI consistent with those criteria (McDonald, 2001, Ann Neurol)
- Onset of first MS symptoms within 3 years prior to Screening as of signing the ICF
- Expanded Disability Status Scale (EDSS) score 0.0 to 3.0 (inclusive) at the screening and Baseline visits
- At least 2 completed clinical episodes of MS in the 2 years prior to study entry (that is, the initial event if within 2 years of study entry plus at least 1 relapse, or at least 2 relapses if the initial event was between 2 and 3 years prior to study entry)
- In addition to the clinical criteria, at least 1 enhancing lesion on any 1 of up to 4 screening gadolinium-enhanced MRI brain scans during a maximum 3-month run-in period (inclusive of the Month 0 Baseline scan)
Критерии невключения
- Previous immunotherapy for MS other than steroids, including treatment with interferons, intravenous immunoglobulin (IVIG), glatiramer acetate, and mitoxantrone
- Personal history of thyroid autoimmune disease
- Personal history of clinically significant autoimmune disease (for example, inflammatory bowel disease, diabetes, lupus, severe asthma)
- History of thyroid carcinoma (previous thyroid adenoma was acceptable and was not considered an exclusion criterion)
- History of malignancy (except for basal cell skin carcinoma if disease-free for at least 5 years)
- Any disability acquired from trauma or another illness that, in the opinion of the Investigator, interfered with evaluation of disability due to MS
- Previous treatment with alemtuzumab
- History of anaphylaxis following exposure to humanized monoclonal antibodies
- Inability to undergo MRI with gadolinium administration
- Female participants of childbearing potential with a positive serum pregnancy test at screening or Baseline
- Male and female participants who did not agree to use effective contraceptive method(s) during the study
- Impaired renal function (that is, serum creatinine greater than or equal to 2 times the upper limit of normal \[ULN\])
- Untreated, major depressive disorder
- Epileptic seizures that were not adequately controlled by treatment
- Suicidal ideation
- Major systemic disease or other illness that, in the opinion of the Investigator, have compromised participant safety or interfered with the interpretation of study results
- Abnormal CD4 count or significantly abnormal thyroid function; presence of anti-thyroid stimulating hormone (TSH) receptor antibodies; known seropositivity for human immunodeficiency (HIV)
- Intolerance of pulsed corticosteroids, especially a history of steroid psychosis
- Presence of a monoclonal paraprotein
- Participants who had any form of MS other than relapsing-remitting
- Participants currently participating in a clinical study of an experimental or unapproved/unlicensed therapy
Источник: ClinicalTrials.gov, NCT00050778 · запись обновлена в реестре 8 января 2015.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 3
- Probability of Participants With Sustained Accumulation of Disability (SAD) — Up to 3 years
- Annualized Relapse Rate — Up to 3 years
Цель исследования
This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis (MS) who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more.
Где проходит
6 центров в 2 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00050778 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.